SAFETY DATA SHEET

2% Xylocaine™ Dental with epinephrine 1:50,000 (Lidocaine Hydrochloride 2% and epinephrine 1:50,000 injection)

2% Xylocaine™ Dental with epinephrine 1:100,000 (Lidocaine Hydrochloride 2% and epinephrine 1:100,000 injection)

SDS-002-XYLOCAINE W/EPI REV 00, March 2017

DENTSPLY International
DENTSPLY Pharmaceutical

Safety Data Sheet


1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1 Product Identifier:

Trade Name (as labeled): 2% Xylocaine™ Dental with epinephrine 1:50,000 (Lidocaine Hydrochloride 2% and epinephrine 1:50,000 injection)

Part/Item Number(s): 20016, 22216

2% Xylocaine™ Dental with epinephrine 1:100,000 (Lidocaine Hydrochloride 2% and epinephrine 1:100,000 injection)

1.2 Relevant Identified Uses of the Substance or Mixture and Uses Advised Against:

Recommended Use: Local anesthetic solution for use in peripheral nerve blocks

Restrictions on Use: For Professional Use Only

1.3 Details of the Supplier of the Safety Data Sheet:

Manufacturer/Supplier Name: DENTSPLY Pharmaceutical

Manufacturer/Supplier Address: 1301 Smile Way

York, PA 17404

Manufacturer/Supplier Telephone Number: 1-800-989-8825

Email address: webmaster@dentsply.com
SAFETY DATA SHEET
2% Xylocaine™ Dental with epinephrine 1:50,000 (Lidocaine Hydrochloride 2% and epinephrine 1:50,000 injection)
2% Xylocaine™ Dental with epinephrine 1:100,000 (Lidocaine Hydrochloride 2% and epinephrine 1:100,000 injection)

SDS-002-XYLOCAINE W/EPI REV 00, March 2017

1.4 Emergency Telephone Number: 1-416-522-3854
Please report all incidents to the company contacts listed above.

2. HAZARDS IDENTIFICATION

2.1 Classification of the Substance or Mixture:

<table>
<thead>
<tr>
<th>GHS Classification:</th>
<th>Health</th>
<th>Environmental</th>
<th>Physical</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU Classification:</td>
<td>Not Hazardous</td>
<td>Not Hazardous</td>
<td>Not Hazardous</td>
</tr>
</tbody>
</table>

2.2 Label Elements:
None Required
Signal Word: None

<table>
<thead>
<tr>
<th>Hazard Phrases</th>
<th>Precautionary Phrases</th>
</tr>
</thead>
<tbody>
<tr>
<td>None Required</td>
<td>None Required</td>
</tr>
</tbody>
</table>

2.3 Other Hazards: None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

3.2 Mixture:

<table>
<thead>
<tr>
<th>Hazardous Components</th>
<th>CAS. #</th>
<th>EINECS #</th>
<th>Classification</th>
<th>WT %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-hazardous ingredients</td>
<td>Mixture</td>
<td>Mixture</td>
<td>Not Hazardous</td>
<td>&lt;98</td>
</tr>
<tr>
<td>Lidocaine Hydrochloride</td>
<td>137-58-6</td>
<td>205-302-8</td>
<td>Xn, Xi, R22, R36 Acute Tox. 4 H302 Eye Irrit. 2A H319</td>
<td>2.0</td>
</tr>
<tr>
<td>Epinephrine</td>
<td>51-42-3</td>
<td>200-098-7</td>
<td>T R24/25 Acute Tox 3 H301, 311</td>
<td>0.001-0.002</td>
</tr>
</tbody>
</table>

Refer to Section 16 for the full text of the GHS and EU Classifications.

4. FIRST AID MEASURES

4.1 Description of First Aid Measures:
<table>
<thead>
<tr>
<th>Eye</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Flush victim’s eyes with large quantities of water for at least 15 minutes, while holding the eyelids apart. Get medical attention if irritation develops or persists.</td>
</tr>
</tbody>
</table>
### SAFETY DATA SHEET

**2% Xylocaine™ Dental with epinephrine 1:50,000 (Lidocaine Hydrochloride 2% and epinephrine 1:50,000 injection)**

**2% Xylocaine™ Dental with epinephrine 1:100,000 (Lidocaine Hydrochloride 2% and epinephrine 1:100,000 injection)**

**SDS-002-XYLOCAINE W/EPI REV 00, March 2017**

<table>
<thead>
<tr>
<th>Skin</th>
<th>Wash skin thoroughly with soap and water. Get medical attention if irritation occurs and persists. Remove and launder clothing before re-use.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inhalation</td>
<td>Remove victim to fresh air. Get medical attention if symptoms of exposure occur.</td>
</tr>
<tr>
<td>Ingestion</td>
<td>If small quantities are swallowed, rinse out mouth with water. Do not induce vomiting. Never give anything by mouth to an unconscious or drowsy person. Get medical attention if you feel unwell.</td>
</tr>
<tr>
<td>Personal Protective Equipment for First Aid Responders</td>
<td>Wear impermeable gloves to avoid skin contact (e.g. nitrile, natural rubber).</td>
</tr>
</tbody>
</table>

4.2 Most Important Symptoms and Effects, Both Acute and Delayed:

May cause slight eye and skin irritation. Skin contact may cause numbness.

4.3 Indication of Any Immediate Medical Attention and Special Treatment Needed:

Immediate medical attention should not be required.

**Note to Physicians (Treatment, Testing, and Monitoring):** Treat symptomatically.

### 5. FIRE-FIGHTING MEASURES

5.1 Extinguishing Media:

Water spray, dry chemical, carbon dioxide, or foam as appropriate for surrounding fire and materials.

5.2 Special Hazards Arising from the Substance or Mixture:

Product is not flammable. Thermal decomposition may yield chlorine, hydrogen chloride, or oxides of nitrogen.

5.3 Advice for Fire-Fighters:

**Fire Fighting Procedures:**

Fight fire from safe distance or protected location. Water may be ineffective unless used as a fine spray or fog. Use water to cool fire-exposed containers. Contain water used in firefighting from entering sewers or natural waterways.

**Precautions for Fire Fighters:**

Firefighters should wear full emergency equipment and approved positive pressure self-contained breathing apparatus. Do not enter fire area without proper protection.

**Recommended Protective Equipment for Fire Fighters:**

<table>
<thead>
<tr>
<th>EYES/FACE</th>
<th>HANDS</th>
<th>RESPIRATORY</th>
<th>THERMAL</th>
</tr>
</thead>
</table>

6. ACCIDENTAL RELEASE MEASURES

### 6.1 Personal Precautions, Protective Equipment and Emergency Procedures:
Avoid contact with skin, eyes or clothing. Wear appropriate protective clothing as described in Section 8.

<table>
<thead>
<tr>
<th>EYES/FACE</th>
<th>HANDS</th>
<th>RESPIRATORY</th>
<th>SKIN</th>
</tr>
</thead>
</table>

#### Recommended Personal Protective Equipment forContainment and Clean-up:

<table>
<thead>
<tr>
<th>EYES/FACE</th>
<th>HANDS</th>
<th>RESPIRATORY</th>
<th>SKIN</th>
</tr>
</thead>
</table>

### 6.2 Environmental Precautions:
Report releases as required by local and national authorities.

### 6.3 Methods and Material for Containment and Cleaning up:
Contain and collect using an inert absorbent material and place in appropriate containers for disposal. Clean spill site with water.

### 6.4 Reference to Other Sections:
Refer to Section 8 for Personal Protective Equipment and Section 13 for Disposal information.
7. HANDLING AND STORAGE

7.1 Precautions for Safe Handling:
Avoid contact with skin, eyes or clothing. Wear protective clothing and equipment as described in Section 8. Avoid breathing mists or vapors. Wash thoroughly with soap and water after handling.

7.2 Conditions for Safe Storage, Including Any Incompatibilities: Store in a cool, dry place. Avoid extremes in temperature.

7.3 Specific End Use(s): For professional use only.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1 Control Parameters:

Occupational Exposure Limits:

<table>
<thead>
<tr>
<th>Non-hazardous Ingredients</th>
<th>United States</th>
<th>Germany</th>
<th>United Kingdom</th>
<th>European Union</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>None Established</td>
<td>None Established</td>
<td>None Established</td>
<td>None Established</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Lidocaine</th>
<th>United States</th>
<th>Germany</th>
<th>United Kingdom</th>
<th>European Union</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>None Established</td>
<td>None Established</td>
<td>None Established</td>
<td>None Established</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Epinephrine Bitartrate</th>
<th>United States</th>
<th>Germany</th>
<th>United Kingdom</th>
<th>European Union</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>None Established</td>
<td>None Established</td>
<td>None Established</td>
<td>None Established</td>
</tr>
</tbody>
</table>

Biological Exposure Limits: None Established
SAFETY DATA SHEET

2% Xylocaine™ Dental with epinephrine 1:50,000 (Lidocaine Hydrochloride 2% and epinephrine 1:50,000 injection)

2% Xylocaine™ Dental with epinephrine 1:100,000 (Lidocaine Hydrochloride 2% and epinephrine 1:100,000 injection)

SDS-002-XYLOCAINE W/EPI REV 00, March 2017

8.2 Exposure Controls:

Appropriate Engineering Controls: Use with local exhaust ventilation to minimize exposure levels.

Individual Protection Measures (PPE):

Specific Eye/face Protection: Follow facility requirements. Wear safety glasses when the possibility exists for eye contact due to splashing or spraying material.

Specific Skin Protection: Follow facility requirements. Wear impervious gloves to prevent skin contact.

Specific Respiratory Protection: Follow facility requirements.

Specific Thermal Hazards: None required.

---

Recommended Personal Protective Equipment

<table>
<thead>
<tr>
<th>EYES/FACE</th>
<th>HANDS</th>
<th>RESPIRATORY</th>
<th>SKIN</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image1.png" alt="Eyes Protection" /></td>
<td><img src="image2.png" alt="Gloves Protection" /></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

9. PHYSICAL AND CHEMICAL PROPERTIES

9.1 Information on Basic Physical and Chemical Properties:

<table>
<thead>
<tr>
<th>Property</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance</td>
<td>Clear, colorless liquid</td>
</tr>
</tbody>
</table>
| Explosive limits | LEL: Not available  
UEL: Not available |
| Odor | Odorless |
| Vapor pressure (mmHg) | 17 mmHg @ 20°C |
| Odor threshold | Not available |
| Vapor density | 0.6 (Air = 1) |
| pH | Not available |
| Relative density | 1.0 |
| Melting/freezing point | 32°F (0°C) |
| Solubility(ies) | Complete in Water |
| Initial boiling point and boiling range | 212°F (100°C) |
| Partition coefficient: n-octanol/water | Not available |
| Flash point | Not flammable (water based) |
| Auto-ignition temperature | Not available |
| Evaporation rate | 1 (Butyl acetate = 1) |
| Decomposition temperature | Not available |
SAFETY DATA SHEET

2% Xylocaine™ Dental with epinephrine 1:50,000 (Lidocaine Hydrochloride 2% and epinephrine 1:50,000 injection)

2% Xylocaine™ Dental with epinephrine 1:100,000 (Lidocaine Hydrochloride 2% and epinephrine 1:100,000 injection)

SDS-002-XYLOCAINE W/EPI REV 00, March 2017

<table>
<thead>
<tr>
<th>Flammability (solid, gas):</th>
<th>Not applicable</th>
<th>Viscosity:</th>
<th>Not available</th>
</tr>
</thead>
<tbody>
<tr>
<td>Explosive Properties:</td>
<td>None</td>
<td>Oxidizing Properties:</td>
<td>None</td>
</tr>
</tbody>
</table>

9.2 Other Information: None available

10. STABILITY AND REACTIVITY

10.1 Reactivity: Stable

10.2 Chemical Stability: Stable.

10.3 Possibility of Hazardous Reactions: None known.

10.4 Conditions to Avoid: None known.

10.5 Incompatible materials: Avoid contact with water-reactive materials and strong reducing agents.

10.6 Hazardous Decomposition Products: None.

11. TOXICOLOGICAL INFORMATION

11.1 Information on Toxicological Effects:

Potential Health Effects:

Eyes: Liquid can cause slight irritation with tears and blurred vision. May cause numbness of sensation.
Skin: May cause slight skin irritation and numbness.
Ingestion: May cause slight gastrointestinal irritation.
Inhalation: May cause slight respiratory tract irritation with coughing and anesthetic effects.

Chronic Health Effects: May cause hypersensitivity.

Irritation: May cause slight eye and skin irritation.

Corrosivity: No data available.

Sensitisation: Allergic and anaphylactic reactions associated with lidocaine in Xylocaine™ can occur in a small amount of the population.

Carcinogenicity: None of the components are listed as carcinogens by OSHA, IARC, NTP, ACGIH or the EU CLP.

Mutagenicity: No data available.
SAFETY DATA SHEET

2% Xylocaine™ Dental with epinephrine 1:50,000 (Lidocaine Hydrochloride 2% and epinephrine 1:50,000 injection)

2% Xylocaine™ Dental with epinephrine 1:100,000 (Lidocaine Hydrochloride 2% and epinephrine 1:100,000 injection)

SDS-002-XYLOCAINE W/EPI REV 00, March 2017

Medical Conditions Aggravated by Exposure: None known.

Acute Toxicity Data:
Lidocaine: Oral rat LD50 317mg/kg
Epinephrine: Oral mouse LD50 4 mg/kg
ATEmix: Oral rat LD50 250,000 mg/kg

Reproductive Toxicity Data: No effects on male or female fertility were observed in rats for epinephrine 1:100,000 administered subcutaneously in doses up to 80 mg/kg/day (approximately 2 times the MRHD based on body surface area). No teratogenic effects were noted in embryo-fetal development studies in which rats or rabbits were treated during the period of organogenesis. Embryotoxicity was seen in rabbits, at maternally toxic doses. In rats, decrease pup survival was seen for dams treated during late pregnancy and lactation, at a dose that was maternally toxic and affected the duration of gestation.

Specific Target Organ Toxicity (STOT):
Single Exposure: Causes central nervous system effects such as drowsiness, confusion, excitability and nervousness. Acts as a depressant on the cardiovascular system.
Repeated Exposure: Repeat or chronic exposure may cause hypersensitivity and the development of methemoglobanemia.

12. ECOLOGICAL INFORMATION

12.1 Toxicity: No data available.

12.2 Persistence and Degradability: No data available.

12.3 Bio-accumulative Potential:
Lidocaine: Log KOW: 2.11; Log BCF: 1.059

12.4 Mobility in Soil: No data available.

12.5 Results of PBT and vPvB Assessment: No data available.

12.6 Other Adverse Effects: No adverse effects are expected

13. DISPOSAL CONSIDERATIONS

13.1 Waste Treatment Methods:
Regulations: Dispose in accordance with all national and local regulations.
Properties (Physical/Chemical) Affecting Disposal: This product will polymerize when exposed to sunlight. Empty containers retain product residues and can be hazardous. Follow all SDS precautions when handling empty containers.
14. TRANSPORT INFORMATION

<table>
<thead>
<tr>
<th></th>
<th>14.1 UN Number</th>
<th>14.2 UN Proper Shipping Name</th>
<th>14.3 Hazard Class(s)</th>
<th>14.4 Packing Group</th>
<th>14.5 Environmental Hazards</th>
</tr>
</thead>
<tbody>
<tr>
<td>DOT</td>
<td>None</td>
<td>Not Regulated</td>
<td>None</td>
<td>None</td>
<td>Not applicable</td>
</tr>
<tr>
<td>ADR/RID</td>
<td>None</td>
<td>Not Regulated</td>
<td>None</td>
<td>None</td>
<td>Not applicable</td>
</tr>
<tr>
<td>IMDG</td>
<td>None</td>
<td>Not Regulated</td>
<td>None</td>
<td>None</td>
<td>Not applicable</td>
</tr>
<tr>
<td>IATA/ICAO</td>
<td>None</td>
<td>Not Regulated</td>
<td>None</td>
<td>None</td>
<td>Not applicable</td>
</tr>
</tbody>
</table>


14.7 Transport in Bulk According to Annex II of MARPOL 73/78 and the IBC Code: Not applicable.

15. REGULATORY INFORMATION

15.1 Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture:

U.S. Federal Regulations

Comprehensive Environmental Response and Liability Act of 1980 (CERCLA): This product is not subject to reporting under CERCLA. Many states have more stringent release reporting requirements. Report spills required under federal, state and local regulations.

Toxic Substances Control Act (TSCA): This product is a medical device and not subject to chemical notification requirements.

Clean Water Act (CWA): This material is not regulated under the Clean Water Act.

Clean Air Act (CAA): This material is not regulated under the Clean Air Act.

Superfund Amendments and Reauthorization Act (SARA) Title III Information:

SARA Section 311/312 (40 CFR 370) Hazard Categories:

<table>
<thead>
<tr>
<th>Immediate Hazard:</th>
<th>No</th>
<th>Pressure Hazard:</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delayed Hazard:</td>
<td>No</td>
<td>Reactivity Hazard:</td>
<td>No</td>
</tr>
<tr>
<td>Fire Hazard:</td>
<td>No</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This product contains the following toxic chemical(s) subject to reporting requirements of SARA Section 313
SAFETY DATA SHEET

2% Xylocaine™ Dental with epinephrine 1:50,000 (Lidocaine Hydrochloride 2% and epinephrine 1:50,000 injection)

2% Xylocaine™ Dental with epinephrine 1:100,000 (Lidocaine Hydrochloride 2% and epinephrine 1:100,000 injection)

SDS-002-XYLOCAINE W/EPI REV 00, March 2017

(40 CFR 372):

<table>
<thead>
<tr>
<th>Components</th>
<th>C.A.S. #</th>
<th>WT %</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

State Regulations

**California:** This product contains the following substances known to the state of California to cause cancer and/or reproductive toxicity:

<table>
<thead>
<tr>
<th>Components</th>
<th>C.A.S. #</th>
<th>WT %</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

International Regulations

**Canadian Workplace Hazardous Materials Information System (WHMIS):** Medical devices are not subject to WHMIS.

**Canadian Environmental Protection Act:** This product is a pharmaceutical formulation and not subject to chemical notification requirements.

This SDS has been prepared according to the criteria of the Controlled Products Regulation (CPR) and the SDS contains all of the information required by the CPR.

**European Inventory of Existing Chemicals (EINECS):** This product is a pharmaceutical formulation and not subject to chemical notification requirements.

**EU REACH:** This product is a pharmaceutical formulation and not subject to chemical notification requirements.

**Australian Inventory of Chemical Substances:** This product is a pharmaceutical formulation and not subject to chemical notification requirements.

**China Inventory of Existing Chemicals and Chemical Substances:** This product is a pharmaceutical formulation and not subject to chemical notification requirements.

**Japanese Existing and New Chemical Substances:** This product is a pharmaceutical formulation and not subject to chemical notification requirements.

**Korean Existing Chemicals List:** This product is a pharmaceutical formulation and not subject to chemical notification requirements.

**Philippine Inventory of Chemicals and Chemical Substances:** This product is a pharmaceutical formulation and not subject to chemical notification requirements.

**15.2 Chemical Safety Assessment:** None required.
SAFETY DATA SHEET

2% Xylocaine™ Dental with epinephrine 1:50,000 (Lidocaine Hydrochloride 2% and epinephrine 1:50,000 injection)

2% Xylocaine™ Dental with epinephrine 1:100,000 (Lidocaine Hydrochloride 2% and epinephrine 1:100,000 injection)

SDS-002-XYLOCAINE W/EPI REV 00, March 2017

16. OTHER INFORMATION

HMIS Hazard Rating:
Health – 1  Flammability – 0  Physical Hazard – 0

Full text of Classification abbreviations used in Section 2 and 3:
Xn Harmful
Xi Irritant
T Toxic
R22 Harmful if swallowed.
R24/25 Toxic in contact with skin and if swallowed.
R36 Irritating to eyes.
Acute Tox. 3 Acute Toxicity Category 3
Acute Tox. 4 Acute Toxicity Category 4
Eye Irrit. 2 Eye Irritation Category 2
H301 Toxic if swallowed.
H302 Harmful if swallowed.
H311 Toxic in contact with skin.
H319 Causes serious eye irritation.

Supersedes: 3 November 2014
Date of Current Revision: 15 March 2017
Revision Summary: Periodic Review and changed the numbering from MSDS-018 to SDS-002 rev00

Data Sources: US NLM ChemID Plus and HSDB, Substance SDS for components, IUCLID Dataset EU Chemical Bureau, ESIS, Country websites for occupational exposure limits and Septodont SDS.